Advertisement

Topics

Marketing authorization application filed in Europe for Durasert 3-year uveitis treatment

10:30 EDT 22 Jun 2017 | Healio

A marketing authorization application has been filed to the European Medicines Agency for the approval to market Durasert 3-year treatment for posterior segment uveitis, according to a pSivida press release.The treatment has seen its primary efficacy endpoints met in two phase 3 trials, reducing the recurrence of posterior segment uveitis in patients through 6 months.

Original Article: Marketing authorization application filed in Europe for Durasert 3-year uveitis treatment

NEXT ARTICLE

More From BioPortfolio on "Marketing authorization application filed in Europe for Durasert 3-year uveitis treatment"

Advertisement
Quick Search
Advertisement
Advertisement